Summary
Aortic Dissection is a major disease affecting 3-12/100.000 patients/year. Global mortality rates are upto 40% and yet symptoms are hard to diagnose, with today´s treatments not specifically designed for the condition resulting in a high tendency to fail.
Aortyx wants to change that. We have developed a Vascular graft, a “patch” that is inserted via a minimally invasive procedure. It adheres to the fissure, stops the blood flowing between the layers, then promotes natural repair. Complicated, life threatening, Open Heart Surgery is avoided, as well as post-operation failures as we replace today´s rigid ‘stents’ with our highly flexible, almost natural patch.
We have successfully proved the product operation in early pre-clinical trials, have a patent application in progress and the backing of several expert vascular surgeons.
For this phase 1 project we wish to finalise our pre-clinical trial planning, as well as our business planning to create a new vascular grafting company with predicted accumulated incomes of 13.78M€ and 13 employees by 2025.
Aortyx wants to change that. We have developed a Vascular graft, a “patch” that is inserted via a minimally invasive procedure. It adheres to the fissure, stops the blood flowing between the layers, then promotes natural repair. Complicated, life threatening, Open Heart Surgery is avoided, as well as post-operation failures as we replace today´s rigid ‘stents’ with our highly flexible, almost natural patch.
We have successfully proved the product operation in early pre-clinical trials, have a patent application in progress and the backing of several expert vascular surgeons.
For this phase 1 project we wish to finalise our pre-clinical trial planning, as well as our business planning to create a new vascular grafting company with predicted accumulated incomes of 13.78M€ and 13 employees by 2025.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/876061 |
| Start date: | 01-09-2019 |
| End date: | 29-02-2020 |
| Total budget - Public funding: | 71 429,00 Euro - 50 000,00 Euro |
Cordis data
Original description
Aortic Dissection is a major disease affecting 3-12/100.000 patients/year. Global mortality rates are upto 40% and yet symptoms are hard to diagnose, with today´s treatments not specifically designed for the condition resulting in a high tendency to fail.Aortyx wants to change that. We have developed a Vascular graft, a “patch” that is inserted via a minimally invasive procedure. It adheres to the fissure, stops the blood flowing between the layers, then promotes natural repair. Complicated, life threatening, Open Heart Surgery is avoided, as well as post-operation failures as we replace today´s rigid ‘stents’ with our highly flexible, almost natural patch.
We have successfully proved the product operation in early pre-clinical trials, have a patent application in progress and the backing of several expert vascular surgeons.
For this phase 1 project we wish to finalise our pre-clinical trial planning, as well as our business planning to create a new vascular grafting company with predicted accumulated incomes of 13.78M€ and 13 employees by 2025.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
